Rui Kang Pharmaceutical Group Investments Limited announced that the group is expected to continue to record a loss for the year ended 31 December 2015 but such loss is expected to be reduced by not less than 15% as compared with a loss attributable to owners of the company of approximately HKD 82.9 million for the corresponding period in 2014. Such improvement in the financial performance of the Group for the year ended December 31, 2015 was mainly due to the absence of impairment loss on goodwill of approximately HKD 8.2 million in respect of its certain subsidiaries as recognized in the corresponding period in 2014; the absence of the loss of approximately HKD 5.89 million on deemed disposal of partial interest in a joint venture company as recorded in the corresponding period in 2014; and (iii) the decrease in net loss on financial assets at fair value through profit or loss for the year ended December 31, 2015 as compared with that in the corresponding period in 2014.